Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

Donata Verdelli, Lucia Nobili, Katia Todoerti, Daniela Intini, Maria Cosenza, Monica Civallero, Jessika Bertacchini, Giorgio Lambertenghi Deliliers, Stefano Sacchi, Luigia Lombardi, Antonino Neri

Research output: Contribution to journalArticle

Abstract

The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalHematological Oncology
Volume27
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Protein C Inhibitor
Protein Kinase Inhibitors
Multiple Myeloma
Protein Kinase C
Down-Regulation
Cell Line
B-Cell Maturation Antigen
TNF Receptor-Associated Factor 5
Cell Proliferation
Gene Expression Profiling
Hematologic Neoplasms
Microarray Analysis
Plasma Cells
Genes
Bone Marrow
Western Blotting
enzastaurin
Apoptosis
Pharmaceutical Preparations

Keywords

  • Cell line
  • Enzastaurin
  • Gene expression profiling
  • Molecular pathway
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. / Verdelli, Donata; Nobili, Lucia; Todoerti, Katia; Intini, Daniela; Cosenza, Maria; Civallero, Monica; Bertacchini, Jessika; Deliliers, Giorgio Lambertenghi; Sacchi, Stefano; Lombardi, Luigia; Neri, Antonino.

In: Hematological Oncology, Vol. 27, No. 1, 2009, p. 23-30.

Research output: Contribution to journalArticle

Verdelli, D, Nobili, L, Todoerti, K, Intini, D, Cosenza, M, Civallero, M, Bertacchini, J, Deliliers, GL, Sacchi, S, Lombardi, L & Neri, A 2009, 'Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression', Hematological Oncology, vol. 27, no. 1, pp. 23-30. https://doi.org/10.1002/hon.875
Verdelli, Donata ; Nobili, Lucia ; Todoerti, Katia ; Intini, Daniela ; Cosenza, Maria ; Civallero, Monica ; Bertacchini, Jessika ; Deliliers, Giorgio Lambertenghi ; Sacchi, Stefano ; Lombardi, Luigia ; Neri, Antonino. / Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. In: Hematological Oncology. 2009 ; Vol. 27, No. 1. pp. 23-30.
@article{0b9df69ad37545658110312930c89608,
title = "Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression",
abstract = "The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM.",
keywords = "Cell line, Enzastaurin, Gene expression profiling, Molecular pathway, Multiple myeloma",
author = "Donata Verdelli and Lucia Nobili and Katia Todoerti and Daniela Intini and Maria Cosenza and Monica Civallero and Jessika Bertacchini and Deliliers, {Giorgio Lambertenghi} and Stefano Sacchi and Luigia Lombardi and Antonino Neri",
year = "2009",
doi = "10.1002/hon.875",
language = "English",
volume = "27",
pages = "23--30",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "1",

}

TY - JOUR

T1 - Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

AU - Verdelli, Donata

AU - Nobili, Lucia

AU - Todoerti, Katia

AU - Intini, Daniela

AU - Cosenza, Maria

AU - Civallero, Monica

AU - Bertacchini, Jessika

AU - Deliliers, Giorgio Lambertenghi

AU - Sacchi, Stefano

AU - Lombardi, Luigia

AU - Neri, Antonino

PY - 2009

Y1 - 2009

N2 - The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM.

AB - The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM.

KW - Cell line

KW - Enzastaurin

KW - Gene expression profiling

KW - Molecular pathway

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=65249135021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249135021&partnerID=8YFLogxK

U2 - 10.1002/hon.875

DO - 10.1002/hon.875

M3 - Article

C2 - 18759374

AN - SCOPUS:65249135021

VL - 27

SP - 23

EP - 30

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 1

ER -